ะ—ะฐะณั€ัƒะทะบะฐ ะฒะธะดะตะพ...

ะะต ัƒะดะฐะปะพััŒ ะทะฐะณั€ัƒะทะธั‚ัŒ ะฒะธะดะตะพ

ะะฐ ะณะปะฐะฒะฝัƒัŽ

๐€๐’๐‡ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“: KeloniaTx presented convincing late-breaking data at ASH today from its initial patients in multiple myeloma suggesting that in vivo CAR-T is on track to be a next innovation. Full video:

BiotechTV's profile picture

BiotechTV

11,370 subscribers

21,783 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 7 ะผะตััั†ะตะฒ ะฝะฐะทะฐะด โ€ขvia X (Twitter)

LIVE

Anya Rossiโ€ข Live Now

Private livecam show

ะšะพะผะผะตะฝั‚ะฐั€ะธะธ: 0

ะะตั‚ ะดะพัั‚ัƒะฟะฝั‹ั… ะบะพะผะผะตะฝั‚ะฐั€ะธะตะฒ

ะ—ะดะตััŒ ะฟะพัะฒัั‚ัั ะบะพะผะผะตะฝั‚ะฐั€ะธะธ ะธะท ะพั€ะธะณะธะฝะฐะปัŒะฝะพะณะพ ะฟะพัั‚ะฐ

ะŸะพั…ะพะถะธะต ะฒะธะดะตะพ

๐€๐’๐‡ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“: Checking in (quickly) with Terns Pharmaceuticals CEO Amy Burroughs on the tern-701 data at ASH. $TERN
5:58

๐€๐’๐‡ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“: Checking in (quickly) with Terns Pharmaceuticals CEO Amy Burroughs on the tern-701 data at ASH. $TERN

BiotechTV

18,704 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 7 ะผะตััั†ะตะฒ ะฝะฐะทะฐะด

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Marea Therapeutics today announced acceptance of a late-breaker at #EASCongress2025 for its ANGPTL4 inhibitor - believed to be the first ever clinical data presented for this lipid lowering target. Full video:
6:12

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Marea Therapeutics today announced acceptance of a late-breaker at #EASCongress2025 for its ANGPTL4 inhibitor - believed to be the first ever clinical data presented for this lipid lowering target. Full video:

BiotechTV

14,073 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 1 ะณะพะด ะฝะฐะทะฐะด

๐€๐’๐‡ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“: Corvus CEO Richard Miller believes that ITK inhibitors can have the same broad impact on T-cell diseases as BTK inhibitors have had on B-cell diseases - he would know. $CRVS Full video:
3:33

๐€๐’๐‡ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“: Corvus CEO Richard Miller believes that ITK inhibitors can have the same broad impact on T-cell diseases as BTK inhibitors have had on B-cell diseases - he would know. $CRVS Full video:

BiotechTV

17,673 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 7 ะผะตััั†ะตะฒ ะฝะฐะทะฐะด

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: After switching to a new GalNAc-LNP delivery vehicle a year ago, @VerveTx today announced the initial safety and efficacy data from its VERVE-102 PCSK9 based editor. Co-Founder & CEO Sek Kathiresan MD covers the data. $VERV Full video:
5:19

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: After switching to a new GalNAc-LNP delivery vehicle a year ago, @VerveTx today announced the initial safety and efficacy data from its VERVE-102 PCSK9 based editor. Co-Founder & CEO Sek Kathiresan MD covers the data. $VERV Full video:

BiotechTV

22,484 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 1 ะณะพะด ะฝะฐะทะฐะด

CAR-T for Glioblastoma: Penn Medicine's Dr. Donald O'Rourke describes advances being seen today in using CAR-T against glioblastoma. Penn Medicine - Abramson Cancer Center Full video:
1:23

CAR-T for Glioblastoma: Penn Medicine's Dr. Donald O'Rourke describes advances being seen today in using CAR-T against glioblastoma. Penn Medicine - Abramson Cancer Center Full video:

BiotechTV

17,518 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 2 ะปะตั‚ ะฝะฐะทะฐะด

๐€๐’๐‚๐Ž ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ”: Bicara Therapeutics is presenting long-term follow up data at ASCO that it believes shows durability derived from choosing TGF-ฮฒ with EGFR for its fusion protein in HPV negative head & neck. $BCAX #ASCO26 Full video:
1:56

๐€๐’๐‚๐Ž ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ”: Bicara Therapeutics is presenting long-term follow up data at ASCO that it believes shows durability derived from choosing TGF-ฮฒ with EGFR for its fusion protein in HPV negative head & neck. $BCAX #ASCO26 Full video:

BiotechTV

11,059 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 1 ะผะตััั† ะฝะฐะทะฐะด

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Roche will pay Manifold Bio $55M up front, and up to $2B in milestones, to collaborate on multiple next-generation brain shuttles for neurological diseases. Full video:
4:17

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Roche will pay Manifold Bio $55M up front, and up to $2B in milestones, to collaborate on multiple next-generation brain shuttles for neurological diseases. Full video:

BiotechTV

18,780 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 8 ะผะตััั†ะตะฒ ะฝะฐะทะฐะด

๐…๐ซ๐จ๐ฆ ๐๐˜๐’๐„: ArsenalBio Co-Founder & CEO ken drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features. Full video:
3:45

๐…๐ซ๐จ๐ฆ ๐๐˜๐’๐„: ArsenalBio Co-Founder & CEO ken drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features. Full video:

BiotechTV

11,057 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 1 ะณะพะด ะฝะฐะทะฐะด

๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“ ๐•๐ž๐ง๐ญ๐ฎ๐ซ๐ž ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐‘๐ž๐ฉ๐จ๐ซ๐ญ: Every year at this time, HSBC Innovation Banking's Jon Norris publishes his widely-read full year venture report. DOWNLOAD THE FREE REPORT HERE: HSBC Innovation Banking | #sponsored
1:06

๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“ ๐•๐ž๐ง๐ญ๐ฎ๐ซ๐ž ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐‘๐ž๐ฉ๐จ๐ซ๐ญ: Every year at this time, HSBC Innovation Banking's Jon Norris publishes his widely-read full year venture report. DOWNLOAD THE FREE REPORT HERE: HSBC Innovation Banking | #sponsored

BiotechTV

16,954 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 6 ะผะตััั†ะตะฒ ะฝะฐะทะฐะด

๐…๐ซ๐จ๐ฆ ๐ญ๐ก๐ž ๐๐š๐ฒ ๐€๐ซ๐ž๐š: Gordian Biotechnology announced that it will be using its unique large-scale in vivo screening process to help Pfizer look for new targets against obesity. Co Founder & CSO Martin Borch Jensen explains how it works. Full video:
2:56

๐…๐ซ๐จ๐ฆ ๐ญ๐ก๐ž ๐๐š๐ฒ ๐€๐ซ๐ž๐š: Gordian Biotechnology announced that it will be using its unique large-scale in vivo screening process to help Pfizer look for new targets against obesity. Co Founder & CSO Martin Borch Jensen explains how it works. Full video:

BiotechTV

13,213 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 4 ะผะตััั†ะตะฒ ะฝะฐะทะฐะด

๐€๐’๐‡ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ’: Legend Biotech CEO Ying Huang on moving Carvykti into earlier settings, potential future competition, beyond BCMA, and more. #ASH24 $LEGN Full video:
0:48

๐€๐’๐‡ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ’: Legend Biotech CEO Ying Huang on moving Carvykti into earlier settings, potential future competition, beyond BCMA, and more. #ASH24 $LEGN Full video:

BiotechTV

16,621 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 1 ะณะพะด ะฝะฐะทะฐะด

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month. $ABVX Watch the full video:
3:01

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month. $ABVX Watch the full video:

BiotechTV

22,202 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 16 ะดะฝะตะน ะฝะฐะทะฐะด

๐€๐’๐†๐‚๐“ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“: Physicians and scientists raced to make a bespoke gene editing therapy for an infant who urgently needed one in months - a first hand account by Kiran Musunuru. #ASGCT2025 Full video:
10:34

๐€๐’๐†๐‚๐“ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“: Physicians and scientists raced to make a bespoke gene editing therapy for an infant who urgently needed one in months - a first hand account by Kiran Musunuru. #ASGCT2025 Full video:

BiotechTV

22,275 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 1 ะณะพะด ะฝะฐะทะฐะด

๐๐ซ๐ข๐ ๐ก๐ญ ๐Œ๐ข๐ง๐๐ฌ: Dana-Farber investigators Toni Choueiri, MD and Patrick Ott describe a personalized cancer vaccine trial in kidney cancer that was published in Nature. All nine patients did not see their cancer recur. Full video:
4:28

๐๐ซ๐ข๐ ๐ก๐ญ ๐Œ๐ข๐ง๐๐ฌ: Dana-Farber investigators Toni Choueiri, MD and Patrick Ott describe a personalized cancer vaccine trial in kidney cancer that was published in Nature. All nine patients did not see their cancer recur. Full video:

BiotechTV

13,789 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 1 ะณะพะด ะฝะฐะทะฐะด

๐๐ซ๐ข๐ ๐ก๐ญ ๐Œ๐ข๐ง๐๐ฌ: William Blair Senior Biotech Analyst Andy Hsieh reacts to today's oral obesity data from Viking's VK2735 and recent data from Lilly's orforglipron. $VKTX $LLY Full video:
13:02

๐๐ซ๐ข๐ ๐ก๐ญ ๐Œ๐ข๐ง๐๐ฌ: William Blair Senior Biotech Analyst Andy Hsieh reacts to today's oral obesity data from Viking's VK2735 and recent data from Lilly's orforglipron. $VKTX $LLY Full video:

BiotechTV

68,717 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 11 ะผะตััั†ะตะฒ ะฝะฐะทะฐะด

Company News: Intellia Therapeutics's Chief Scientific Officer elaborates on the news that the company successfully redosed patients with a CRISPR-based and LNP delivered therapy. $NTLA Full video:
4:26

Company News: Intellia Therapeutics's Chief Scientific Officer elaborates on the news that the company successfully redosed patients with a CRISPR-based and LNP delivered therapy. $NTLA Full video:

BiotechTV

21,947 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 2 ะปะตั‚ ะฝะฐะทะฐะด

Freak visuals from Ludhiana in Punjab. A man stole a Baleno car. He was intercepted and cornered. What happened next? Multiple speeding laps in forward and reverse - ramming into anything that came its way on the narrow road.
2:15

Freak visuals from Ludhiana in Punjab. A man stole a Baleno car. He was intercepted and cornered. What happened next? Multiple speeding laps in forward and reverse - ramming into anything that came its way on the narrow road.

Piyush Rai

160,101 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 2 ะผะตััั†ะตะฒ ะฝะฐะทะฐะด

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Aerska launched in the UK today with $21M in financing to develop RNAi medicines for neurological conditions that are delivered to the brain via 'brain shuttle' technologies. CEO Jack O'Meara explains. Full video:
4:35

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Aerska launched in the UK today with $21M in financing to develop RNAi medicines for neurological conditions that are delivered to the brain via 'brain shuttle' technologies. CEO Jack O'Meara explains. Full video:

BiotechTV

19,198 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 9 ะผะตััั†ะตะฒ ะฝะฐะทะฐะด

Programming note: BiotechTV will be broadcasting from the AI x Bio Summit at NYSE ๐Ÿ› on Thursday, July 25th. Tune in to hear from top companies and investors in the space.
1:03

Programming note: BiotechTV will be broadcasting from the AI x Bio Summit at NYSE ๐Ÿ› on Thursday, July 25th. Tune in to hear from top companies and investors in the space.

BiotechTV

12,058 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 2 ะปะตั‚ ะฝะฐะทะฐะด

This is the full video of the hardest version of the task: t-shirt folding from unstructured initial states. This setting really requires at least some strategy, since the robot first has to spread the shirt before it can complete the fold. Full details on data collection strategies in the blog below. ๐Ÿ‘‡
1:37

This is the full video of the hardest version of the task: t-shirt folding from unstructured initial states. This setting really requires at least some strategy, since the robot first has to spread the shirt before it can complete the fold. Full details on data collection strategies in the blog below. ๐Ÿ‘‡

LeRobot

53,858 ะฟั€ะพัะผะพั‚ั€ะพะฒ โ€ข 3 ะผะตััั†ะตะฒ ะฝะฐะทะฐะด